Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHA:603567)
China · Delayed Price · Currency is CNY 7.52
+0.24 (3.30%)
May 20, 2026, 1:05 PM CST
SHA:603567 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 509.95 | 797.34 | 2,677 | 3,084 | 4,199 | 4,120 |
Other Revenue | 0.49 | 0.73 | 26.93 | 54.11 | 14.68 | 6.5 |
| 510.45 | 798.06 | 2,704 | 3,138 | 4,214 | 4,127 | |
Revenue Growth (YoY) | -75.20% | -70.48% | -13.84% | -25.53% | 2.12% | 21.24% |
Cost of Revenue | 882.78 | 820.12 | 1,334 | 1,846 | 3,539 | 2,829 |
Gross Profit | -372.33 | -22.06 | 1,370 | 1,292 | 675.25 | 1,298 |
Selling, General & Admin | 319.41 | 364.69 | 575.22 | 979.01 | 915.17 | 952.16 |
Research & Development | 51.65 | 46.35 | 37.99 | 80.22 | 70.95 | 55.23 |
Other Operating Expenses | -15.31 | -15.24 | 36.03 | 43.79 | -64.36 | -24.14 |
Operating Expenses | 355.75 | 395.8 | 767.06 | 1,107 | 891.96 | 1,028 |
Operating Income | -728.08 | -417.86 | 602.9 | 185.52 | -216.71 | 270.38 |
Interest Expense | - | - | -137.09 | -135.41 | -138.68 | -144.79 |
Interest & Investment Income | - | - | 22.69 | 471.68 | 38.06 | 251.32 |
Currency Exchange Gain (Loss) | - | - | - | - | -0 | -0 |
Other Non Operating Income (Expenses) | -837.01 | -814.85 | 9.22 | -88.59 | 26.83 | -22.32 |
EBT Excluding Unusual Items | -1,561 | -1,233 | 497.73 | 433.2 | -290.5 | 354.6 |
Impairment of Goodwill | - | - | - | -2.4 | -1.28 | - |
Gain (Loss) on Sale of Investments | -12.08 | -12.11 | -9.69 | 0.6 | -1.75 | -0.15 |
Gain (Loss) on Sale of Assets | -1.46 | -0.61 | -1.68 | -0.26 | 39.33 | -1.11 |
Asset Writedown | -366.09 | -381.97 | -0.63 | -1.51 | - | -0.09 |
Other Unusual Items | - | - | 37.75 | 48.72 | 552.68 | 101.49 |
Pretax Income | -1,941 | -1,627 | 523.47 | 478.35 | 298.48 | 454.75 |
Income Tax Expense | -315.83 | -257.47 | 87.08 | 10.76 | 107.55 | 121.99 |
Earnings From Continuing Operations | -1,625 | -1,370 | 436.39 | 467.59 | 190.93 | 332.76 |
Minority Interest in Earnings | 3.11 | 3.4 | 1.82 | 5.15 | -5.49 | -0.66 |
Net Income | -1,622 | -1,367 | 438.22 | 472.74 | 185.44 | 332.1 |
Net Income to Common | -1,622 | -1,367 | 438.22 | 472.74 | 185.44 | 332.1 |
Net Income Growth | - | - | -7.30% | 154.93% | -44.16% | -23.88% |
Shares Outstanding (Basic) | 940 | 940 | 940 | 939 | 941 | 865 |
Shares Outstanding (Diluted) | 940 | 940 | 940 | 940 | 941 | 865 |
Shares Change (YoY) | -0.05% | -0.01% | -0.01% | -0.14% | 8.87% | 1.82% |
EPS (Basic) | -1.73 | -1.45 | 0.47 | 0.50 | 0.20 | 0.38 |
EPS (Diluted) | -1.73 | -1.45 | 0.47 | 0.50 | 0.20 | 0.38 |
EPS Growth | - | - | -7.30% | 155.28% | -48.71% | -25.24% |
Free Cash Flow | 602 | 253.57 | -24.84 | -573.38 | -731.07 | -882.57 |
Free Cash Flow Per Share | 0.64 | 0.27 | -0.03 | -0.61 | -0.78 | -1.02 |
Dividend Per Share | - | - | 0.150 | 0.200 | 0.028 | 0.106 |
Dividend Growth | - | - | -25.00% | 614.29% | -73.58% | - |
Gross Margin | -72.94% | -2.76% | 50.67% | 41.18% | 16.02% | 31.45% |
Operating Margin | -142.64% | -52.36% | 22.30% | 5.91% | -5.14% | 6.55% |
Profit Margin | -317.72% | -171.23% | 16.21% | 15.06% | 4.40% | 8.05% |
Free Cash Flow Margin | 117.94% | 31.77% | -0.92% | -18.27% | -17.35% | -21.39% |
EBITDA | -558 | -250.98 | 756.94 | 364.32 | -59.75 | 405.93 |
EBITDA Margin | -109.32% | -31.45% | 27.99% | 11.61% | -1.42% | 9.84% |
D&A For EBITDA | 170.08 | 166.88 | 154.04 | 178.8 | 156.95 | 135.55 |
EBIT | -728.08 | -417.86 | 602.9 | 185.52 | -216.71 | 270.38 |
EBIT Margin | -142.64% | -52.36% | 22.30% | 5.91% | -5.14% | 6.55% |
Effective Tax Rate | - | - | 16.63% | 2.25% | 36.03% | 26.82% |
Revenue as Reported | - | - | 2,707 | 3,144 | 4,219 | 4,130 |
Advertising Expenses | - | - | 15.94 | 10.42 | 3.57 | 2.17 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.